Loading data
REPLNasdaq
| Unit: USD | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Research and development expense | 221.18 m USD | 189.45 m USD | 174.96 m USD | 126.53 m USD | 79.55 m USD |
| Selling, general and administrative expense | 98.74 m USD | 72.18 m USD | — | — | — |
| Operating profit | -319.92 m USD | -261.63 m USD | -234.77 m USD | -177.08 m USD | -118.31 m USD |
| Profit before tax | -314.49 m USD | -246.83 m USD | -215.39 m USD | -174 m USD | -118.04 m USD |
| Income tax expense | -551 k USD | 500 k USD | 400 k USD | 288 k USD | 0 USD |
| Net income (reported basis) | -313.9 m USD | -247.3 m USD | -215.8 m USD | -174.3 m USD | -118 m USD |
| Net income attributable to common shareholders | -313.94 m USD | -247.3 m USD | -215.79 m USD | -174.28 m USD | -118.04 m USD |
| Basic earnings per share | -3.38 USD/share | -3.07 USD/share | -3.24 USD/share | -2.99 USD/share | -2.26 USD/share |
| Diluted earnings per share | -3.38 USD/share | -3.07 USD/share | -3.24 USD/share | -2.99 USD/share | -2.26 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.